Artivion (NYSE:AORT – Get Free Report) and Avita Medical (NASDAQ:RCEL – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, dividends, earnings, institutional ownership and risk.
Institutional and Insider Ownership
86.4% of Artivion shares are owned by institutional investors. Comparatively, 27.7% of Avita Medical shares are owned by institutional investors. 6.3% of Artivion shares are owned by company insiders. Comparatively, 2.2% of Avita Medical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Earnings and Valuation
This table compares Artivion and Avita Medical”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Artivion | $471.47 million | 2.59 | $9.77 million | ($0.07) | -357.94 |
| Avita Medical | $71.61 million | 6.74 | -$48.59 million | ($1.44) | -10.89 |
Artivion has higher revenue and earnings than Avita Medical. Artivion is trading at a lower price-to-earnings ratio than Avita Medical, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Artivion has a beta of 1.31, suggesting that its stock price is 31% more volatile than the S&P 500. Comparatively, Avita Medical has a beta of 2.03, suggesting that its stock price is 103% more volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of current ratings for Artivion and Avita Medical, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Artivion | 1 | 0 | 7 | 0 | 2.75 |
| Avita Medical | 1 | 1 | 5 | 0 | 2.57 |
Artivion presently has a consensus target price of $42.86, indicating a potential upside of 71.05%. Avita Medical has a consensus target price of $12.20, indicating a potential downside of 22.19%. Given Artivion’s stronger consensus rating and higher probable upside, equities research analysts plainly believe Artivion is more favorable than Avita Medical.
Profitability
This table compares Artivion and Avita Medical’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Artivion | -0.67% | 6.07% | 2.93% |
| Avita Medical | -56.96% | N/A | -78.53% |
Summary
Artivion beats Avita Medical on 11 of the 14 factors compared between the two stocks.
About Artivion
Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo. It offers E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, a stent graft system for the treatment of infrarenal abdominal aortic aneurysms. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.
About Avita Medical
AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California.
Receive News & Ratings for Artivion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Artivion and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.png){kind=logo}
